Luminec Pharmaceuticals Completes NIH, BARDA Coronavirus Submission

Share Article

Promising COVID-19 countermeasure has contributed to successful treatment of other Coronavirus strains

Luminec Pharmaceuticals
Luminec Pharmaceuticals has successfully used these formulations for several decades to treat viral infections in both human and veterinary applications in a number of countries around the world.

Luminec Pharmaceuticals has completed its initial submission and request for meeting to the National Institute of Allergies and Infectious Diseases (NIAID) and to the Biomedical Advanced Research and Development Authority (BARDA) under the “Medical Countermeasures: Coronawatch” program.

“We believe the scientific research and peer-reviewed papers we have submitted, along with past and current patient records, provide strong evidence of the efficacy of our combined therapy of CRO-50 (ribonuclease) and X-2 (stable thiamine formulation) in COVID-19 patients, as well as for other Coronavirus infections,” said Luminec Pharmaceuticals CEO Mark T. Crane. “With the leadership of executive board member Susana Alcázar, MD, PhD, Luminec Pharmaceuticals has successfully used these formulations for several decades to treat viral infections in both human and veterinary applications in a number of countries around the world.”

“We look forward to presenting further data and information to the agency about our therapeutic countermeasure, and to receiving feedback and suggestions on designing and executing an expedited regulatory pathway to FDA approval,” said Luminec Chief Science Officer Stephen Holt, MD, DSc, PhD. “We feel honored to offer our research and records to help mitigate the current, and potential future, viral pandemics.”

About Luminec Pharmaceuticals

Headquartered in Carlsbad, CA, Luminec Pharmaceuticals currently offers a unique array of all-natural OTC products and clinical services for both human and animal use. Luminec’s products include natural proprietary formulations based on the Schutt Paradigm of Free Amino Ion Alignment & Molecular Stability, in combination with proprietary partner technologies with a cutting edge delivery technology, oral and topically, composed of charged delivery spheres that encapsulate and transport active compounds into the system, naturally.

Luminec Pharmaceuticals is a wholly owned subsidiary of Luminec Holding Corporation, a private company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay Mitchell
Visit website